ATE525082T1 - Compstatin-analoga mit verbesserter wirkung - Google Patents
Compstatin-analoga mit verbesserter wirkungInfo
- Publication number
- ATE525082T1 ATE525082T1 AT03759343T AT03759343T ATE525082T1 AT E525082 T1 ATE525082 T1 AT E525082T1 AT 03759343 T AT03759343 T AT 03759343T AT 03759343 T AT03759343 T AT 03759343T AT E525082 T1 ATE525082 T1 AT E525082T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- improved effects
- peptides
- disclosed
- compstatin analogues
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 2
- RDTRHBCZFDCUPW-KWICJJCGSA-N 2-[(4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-4-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-34-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10,13-bis(1h-imidazol-5-ylmethyl)-19-(1h-indol Chemical class C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)C(C)C)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 RDTRHBCZFDCUPW-KWICJJCGSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 101710131943 40S ribosomal protein S3a Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000816 peptidomimetic Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41222002P | 2002-09-20 | 2002-09-20 | |
| PCT/US2003/029653 WO2004026328A1 (en) | 2002-09-20 | 2003-09-22 | Compstatin analogs with improved activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE525082T1 true ATE525082T1 (de) | 2011-10-15 |
Family
ID=32030834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03759343T ATE525082T1 (de) | 2002-09-20 | 2003-09-22 | Compstatin-analoga mit verbesserter wirkung |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US7989589B2 (de) |
| EP (3) | EP2311480B1 (de) |
| JP (3) | JP4614222B2 (de) |
| AT (1) | ATE525082T1 (de) |
| AU (1) | AU2003275075A1 (de) |
| CA (2) | CA2502690C (de) |
| CY (1) | CY1112198T1 (de) |
| DK (1) | DK1549333T3 (de) |
| ES (1) | ES2373649T3 (de) |
| PT (1) | PT1549333E (de) |
| SI (1) | SI1549333T1 (de) |
| WO (1) | WO2004026328A1 (de) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1549333T3 (da) * | 2002-09-20 | 2012-01-16 | Univ Pennsylvania | Compstatinanaloge med forbedret aktivitet |
| WO2005118020A1 (en) * | 2004-04-21 | 2005-12-15 | Allvivo, Inc. | Surface coating comprising bioactive compound |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| CA2625206C (en) * | 2005-10-08 | 2021-12-07 | Potentia Pharmaceuticals, Inc. | Compstatin and analogs thereof for eye disorders |
| AU2013200981B2 (en) * | 2005-11-28 | 2016-01-14 | The Trustees Of The University Of Pennsylvania | Potent compstatin analogs |
| CN106188239B (zh) | 2005-11-28 | 2020-01-07 | 宾夕法尼亚州大学理事会 | 有效的坎普他汀类似物 |
| AU2008214359B2 (en) * | 2007-02-05 | 2014-01-16 | Apellis Pharmaceuticals, Inc. | Local complement inhibition for treatment of complement-mediated disorders |
| US8442776B2 (en) | 2007-06-08 | 2013-05-14 | The Trustees Of The University Of Pennsylvania | Structure of compstatin-C3 complex and use for rational drug design |
| US8563259B2 (en) | 2007-06-29 | 2013-10-22 | The Trustees Of The University Of Pennsylvania | Complement-mediated thrombophilic assay |
| US20110092446A1 (en) * | 2007-07-20 | 2011-04-21 | Cedric Francois | Compositions and methods for treatment of trauma |
| WO2009046198A2 (en) * | 2007-10-02 | 2009-04-09 | Potentia Pharmaceuticals, Inc. | Sustained delivery of compstatin analogs from gels |
| CA2718588A1 (en) | 2008-02-19 | 2009-08-27 | The Trustees Of The University Of Pennsylvania | Complement inhibitors as therapeutic agents for treatment of cancer |
| WO2009121065A2 (en) * | 2008-03-28 | 2009-10-01 | Apellis Ag | Modulation and repletion/enhancement of the complement system for treatment of trauma |
| WO2010022149A1 (en) | 2008-08-20 | 2010-02-25 | The Trustees Of The University Of Pennsylvania | Complement inhibitors for treatment of injury form intracerebral hemorrhage |
| US8445190B2 (en) | 2008-09-30 | 2013-05-21 | The Trustees Of The University Of Pennsylvania | Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors |
| CN102458438A (zh) * | 2009-05-01 | 2012-05-16 | 宾夕法尼亚州大学理事会 | 具有肽骨架和c-末端修饰的经修饰补体抑素 |
| US9291622B2 (en) | 2009-05-21 | 2016-03-22 | Apellis Pharmaceuticals, Inc. | Complement assays and uses thereof |
| US20110104154A1 (en) | 2009-10-30 | 2011-05-05 | Alcon Research, Ltd. | Single nucleotide polymorphisms and genes associated with age-related macular degeneration |
| US9358266B2 (en) | 2010-02-25 | 2016-06-07 | The Trustees Of The University Of Pennsylvania | Treatment of sepsis using complement inhibitors |
| US9421240B2 (en) | 2010-06-22 | 2016-08-23 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
| CA2813049A1 (en) | 2010-09-23 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Modified compstatin with improved stability and binding properties |
| WO2012095519A1 (en) | 2011-01-13 | 2012-07-19 | Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie | Potent inhibitors of complement activation |
| US20140219999A1 (en) | 2011-04-01 | 2014-08-07 | The Trustees Of The University Of Pennsylvania | Treatment of colon cancer using complement inhibitors |
| CA2835627C (en) | 2011-05-11 | 2023-01-10 | Apellis Pharmaceuticals, Inc. | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
| WO2012162215A1 (en) | 2011-05-20 | 2012-11-29 | The Trustees Of The University Of Pennsylvania | Promotion of fracture healing using complement inhibitors |
| WO2012174055A1 (en) | 2011-06-13 | 2012-12-20 | The Trustees Of The University Of Pennsylvania | Wound healing using complement inhibitors |
| EP2723361B1 (de) | 2011-06-22 | 2019-10-30 | Apellis Pharmaceuticals, Inc. | Verfahren zur behandlung chronischer erkrankungen mit komplementinhibitoren |
| CA2847862C (en) | 2011-09-07 | 2021-01-12 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved pharmacokinetic properties |
| EP3929206A1 (de) | 2012-11-15 | 2021-12-29 | Apellis Pharmaceuticals, Inc. | Langwirkende compstatin-analoga sowie verwandte zusammensetzungen und verfahren |
| US20160194359A1 (en) * | 2012-11-15 | 2016-07-07 | Apellis Pharmaceuticals, Inc. | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
| US10308687B2 (en) | 2013-03-15 | 2019-06-04 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| CA2931090A1 (en) | 2013-12-12 | 2015-06-18 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
| WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| WO2015142701A1 (en) | 2014-03-17 | 2015-09-24 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved potency and pharmacokinetic properties |
| KR102754019B1 (ko) * | 2014-10-29 | 2025-01-14 | 바이시클러드 리미티드 | Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드 |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| EP3340983B1 (de) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl und heterocyclische verbindungen zur behandlung von immun- und entzündungserkrankungen |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| CA3287719A1 (en) | 2015-10-07 | 2026-03-02 | Apellis Pharmaceuticals, Inc. | Use of long-acting compstatin analog for treating a complement-mediated disorder |
| KR102632860B1 (ko) | 2017-03-01 | 2024-02-02 | 아칠리온 파르마세우티칼스 인코포레이티드 | 의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물 |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| CN116059313A (zh) | 2017-04-07 | 2023-05-05 | 阿佩利斯制药有限公司 | 给药方案以及相关组合物和方法 |
| EP3661493A4 (de) | 2017-08-02 | 2021-04-14 | Achillion Pharmaceuticals, Inc. | Therapiepläne zur behandlung von paroxysmaler nächtlicher hämoglobinurie |
| US11866701B2 (en) | 2017-11-01 | 2024-01-09 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
| KR20240167712A (ko) | 2017-12-15 | 2024-11-27 | 아펠리스 파마슈티컬스 인코포레이티드 | 투여 요법 및 관련 조성물 및 방법 |
| US11965039B2 (en) | 2018-02-27 | 2024-04-23 | Zp Spv 3 K/S | Compstatin analogues and their medical uses |
| WO2019195712A2 (en) | 2018-04-06 | 2019-10-10 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with increased solubility and improved pharmacokinetic properties |
| EP3846803A4 (de) | 2018-09-06 | 2022-08-10 | Achillion Pharmaceuticals, Inc. | Makrocyclische verbindungen zur behandlung von medizinischen erkrankungen |
| US11814363B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Morphic forms of danicopan |
| EP3856164B1 (de) | 2018-09-25 | 2024-08-07 | Achillion Pharmaceuticals, Inc. | Morphische formen von komplementfaktor-d-inhibitoren |
| BR112021011727A2 (pt) | 2018-12-17 | 2021-08-31 | Achillion Pharmaceuticals, Inc | Dosagem direcionada para o tratamento de distúrbios mediados do complemento |
| WO2020198062A1 (en) | 2019-03-22 | 2020-10-01 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| CN114630836A (zh) | 2019-08-27 | 2022-06-14 | 西兰制药第三特殊目的公司 | 补体抑制素类似物及其医学用途 |
| BR112022007540A2 (pt) | 2019-10-22 | 2022-07-12 | Alnylam Pharmaceuticals Inc | Composições de irna de componente complementar c3 e métodos de uso das mesmas |
| CN115362162A (zh) | 2020-02-20 | 2022-11-18 | 艾其林医药公司 | 用于治疗补体因子d介导的障碍的杂芳基化合物 |
| EP4114947A1 (de) | 2020-03-05 | 2023-01-11 | Alnylam Pharmaceuticals, Inc. | Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen |
| EP4142738A1 (de) | 2020-04-30 | 2023-03-08 | Alnylam Pharmaceuticals, Inc. | Komplementfaktor-b (cfb)-irna-zusammensetzungen und verfahren zur verwendung davon |
| WO2021231470A1 (en) | 2020-05-12 | 2021-11-18 | Alexion Pharmaceuticals, Inc. | Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria |
| US20230287051A1 (en) | 2020-07-16 | 2023-09-14 | Zp Spv 3 K/S | Inhibitors of complement factor c3 and their medical uses |
| CA3193488A1 (en) | 2020-09-23 | 2022-03-31 | Jason Allan Wiles | Pharmaceutical compounds for the treatment of complement mediated disorders |
| EP4274896A1 (de) | 2021-01-05 | 2023-11-15 | Alnylam Pharmaceuticals, Inc. | Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon |
| JP2024535850A (ja) | 2021-09-17 | 2024-10-02 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法 |
| CA3234636A1 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
| WO2025176847A1 (en) | 2024-02-21 | 2025-08-28 | Ags Therapeutics Sas | Ocular delivery of active agents via microalgae extracellular vesicles |
| WO2026083442A1 (en) | 2024-10-15 | 2026-04-23 | Mylan Laboratories Limited | Process for the preparation of pegcetacoplan and its purification using chromatography |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2295746A1 (fr) | 1974-12-23 | 1976-07-23 | Francaise Coop Pharma | Nouveaux derives du tryptophane a activite nerveuse centrale renforcee |
| IT1179866B (it) | 1984-12-12 | 1987-09-16 | Rotta Research Lab | Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono |
| US4576750A (en) | 1985-04-22 | 1986-03-18 | Merck & Co., Inc. | Tryptophan derivative |
| US4807097A (en) * | 1986-05-14 | 1989-02-21 | Gammache Richard J | Miniature flashlight |
| US5256642A (en) | 1988-04-01 | 1993-10-26 | The Johns Hopkins University | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
| US5167960A (en) | 1988-08-03 | 1992-12-01 | New England Deaconess Hospital Corporation | Hirudin-coated biocompatible substance |
| WO1991016345A1 (en) | 1990-04-23 | 1991-10-31 | Rijksuniversiteit Te Utrecht | Cyclic peptides and their use |
| ES2204944T3 (es) | 1994-03-03 | 2004-05-01 | Alexion Pharmaceuticals, Inc. | Genes y proteinas de fusion inhibidores del complemento terminal. |
| US5776970A (en) | 1994-04-28 | 1998-07-07 | Yeda Research And Development Co. Ltd. | Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases |
| JP2000505068A (ja) * | 1996-03-13 | 2000-04-25 | トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア | 補体活性化を阻害する新規ペプチド類 |
| US6221621B1 (en) * | 1997-03-06 | 2001-04-24 | Bard Diagnostic Sciences, Inc. | Methods of screening for colorectal cancers in which a complement Factor I or related protein is associated |
| US6169057B1 (en) | 1997-09-04 | 2001-01-02 | The Regents Of The University Of California | Use of tryptophan and analogs as plant growth regulators |
| WO1999013899A1 (en) * | 1997-09-17 | 1999-03-25 | Trustees Of The University Of Pennsylvania | Peptides and peptidomimetics for inhibiting complement activation |
| WO1999052539A1 (en) | 1998-04-10 | 1999-10-21 | Mayo Foundation For Medical Education And Research | Neo-tryptophan |
| DK1549333T3 (da) * | 2002-09-20 | 2012-01-16 | Univ Pennsylvania | Compstatinanaloge med forbedret aktivitet |
| CN106188239B (zh) * | 2005-11-28 | 2020-01-07 | 宾夕法尼亚州大学理事会 | 有效的坎普他汀类似物 |
-
2003
- 2003-09-22 DK DK03759343.1T patent/DK1549333T3/da active
- 2003-09-22 JP JP2004538315A patent/JP4614222B2/ja not_active Expired - Lifetime
- 2003-09-22 EP EP10182327.6A patent/EP2311480B1/de not_active Expired - Lifetime
- 2003-09-22 WO PCT/US2003/029653 patent/WO2004026328A1/en not_active Ceased
- 2003-09-22 CA CA2502690A patent/CA2502690C/en not_active Expired - Lifetime
- 2003-09-22 AT AT03759343T patent/ATE525082T1/de active
- 2003-09-22 EP EP10182239.3A patent/EP2311479B1/de not_active Expired - Lifetime
- 2003-09-22 PT PT03759343T patent/PT1549333E/pt unknown
- 2003-09-22 EP EP03759343A patent/EP1549333B1/de not_active Expired - Lifetime
- 2003-09-22 SI SI200332088T patent/SI1549333T1/sl unknown
- 2003-09-22 US US10/528,496 patent/US7989589B2/en active Active
- 2003-09-22 AU AU2003275075A patent/AU2003275075A1/en not_active Abandoned
- 2003-09-22 CA CA2833202A patent/CA2833202C/en not_active Expired - Lifetime
- 2003-09-22 ES ES03759343T patent/ES2373649T3/es not_active Expired - Lifetime
-
2010
- 2010-07-29 JP JP2010171021A patent/JP2010280688A/ja active Pending
-
2011
- 2011-07-06 US US13/177,140 patent/US8883413B2/en not_active Expired - Lifetime
- 2011-12-20 CY CY20111101259T patent/CY1112198T1/el unknown
-
2013
- 2013-02-06 JP JP2013021599A patent/JP5860573B2/ja not_active Expired - Lifetime
-
2014
- 2014-10-22 US US14/521,075 patent/US20170190741A9/en not_active Abandoned
-
2017
- 2017-07-06 US US15/643,069 patent/US20180118785A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK1549333T3 (da) | 2012-01-16 |
| US20170190741A9 (en) | 2017-07-06 |
| AU2003275075A1 (en) | 2004-04-08 |
| US20180118785A1 (en) | 2018-05-03 |
| HK1156860A1 (en) | 2012-06-22 |
| ES2373649T3 (es) | 2012-02-07 |
| EP2311479B1 (de) | 2014-07-23 |
| JP2006505254A (ja) | 2006-02-16 |
| HK1156862A1 (en) | 2012-06-22 |
| CA2833202A1 (en) | 2004-04-01 |
| EP1549333A4 (de) | 2008-05-28 |
| JP5860573B2 (ja) | 2016-02-16 |
| EP1549333B1 (de) | 2011-09-21 |
| US20150158913A1 (en) | 2015-06-11 |
| US8883413B2 (en) | 2014-11-11 |
| CA2502690A1 (en) | 2004-04-01 |
| US7989589B2 (en) | 2011-08-02 |
| EP2311480A1 (de) | 2011-04-20 |
| US20110275150A1 (en) | 2011-11-10 |
| JP4614222B2 (ja) | 2011-01-19 |
| CA2833202C (en) | 2017-08-01 |
| CA2502690C (en) | 2014-01-28 |
| JP2013138673A (ja) | 2013-07-18 |
| EP2311479A1 (de) | 2011-04-20 |
| EP1549333A1 (de) | 2005-07-06 |
| EP2311480B1 (de) | 2013-06-26 |
| PT1549333E (pt) | 2012-01-03 |
| CY1112198T1 (el) | 2015-12-09 |
| US20100222550A1 (en) | 2010-09-02 |
| SI1549333T1 (sl) | 2012-02-29 |
| WO2004026328A1 (en) | 2004-04-01 |
| JP2010280688A (ja) | 2010-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1549333T3 (da) | Compstatinanaloge med forbedret aktivitet | |
| WO2007062249A3 (en) | Potent compstatin analogs | |
| DK1329458T5 (da) | Peptider som sænker blodglucoseniveauer | |
| ATE368688T1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
| MXPA03002218A (es) | Peptidos antimicrobianos y metodos de uso. | |
| ATE551048T1 (de) | Proteinhydrolysate enthaltende kosmetische zusammensetzungen | |
| ATE278710T1 (de) | Antimikrobiell wirksame peptide | |
| CY1109631T1 (el) | Χρησιμοποιηση πεπτιδιων, τα οποια εχουν παραχθει απο την αα- ή ββ-αλυσιδα του ανθρωπινου ινωδογονου, για τη θεραπεια σοκ | |
| ATE443076T1 (de) | Von protease typ ii spaltbares peptid | |
| EP1735335A4 (de) | Zellabtötende peptide | |
| ATE362487T1 (de) | N-substituierte l-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation | |
| BR9711540A (pt) | Inibidores de protease proteìnico estabilizados e variantes dos mesmos | |
| ATE445634T1 (de) | Antimikrobielle peptide | |
| ATE550345T1 (de) | Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren | |
| ATE336501T1 (de) | Chi-conotoxinpeptide als inhibitoren neuronaler amintransporter | |
| ATE449107T1 (de) | Aus fisch gewonnene peptide und nukleinsäuren der cathelicidin familie und deren verwendung | |
| ATE375360T1 (de) | Peptide mit inhibierender aktivität zur produktion von stickstoffmonoxid | |
| ATE419271T1 (de) | Antimikrobielle peptide | |
| WO2006075253A3 (en) | Peptides for desensitizing subjects allergic to dog hair and dander and compositions containing said peptides. | |
| FI20050753A0 (fi) | Uudet peptidit | |
| DE60008749D1 (de) | Therapeutische peptide aus untersequenzen von bpi | |
| SE0101519D0 (sv) | Nucleic ACID | |
| FI20040655A0 (fi) | Proteiini- ja peptidistabilointi | |
| DE50310131D1 (de) | Peptide mit hohem cysteingehalt | |
| WO2004078776A3 (en) | Ny-eso-1 peptides which bind to class ii molecules and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1549333 Country of ref document: EP |